Live feed07:02:34·375dPRReleasevia QuantisnowOcugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt DiseaseByQuantisnow·Wall Street's wire, on your screen.OCGN· Ocugen Inc.Health Care
